Geneva - The World Health Organization (WHO) said on Wednesday that it was starting the next phase of its Solidarity trial to test three new drugs in hospitalized COVID-19 patients. "The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized patients to test three new drugs in hospitalized COVID-19 patients.
These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients," the WHO said. The drugs in question were donated for the trial by their manufacturers, the statement noted, adding that they are already used against other diseases — artesunate for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients," the WHO said. The drugs in question were donated for the trial by their manufacturers, the statement noted, adding that they are already used against other diseases — artesunate for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
Jesus et Mohammed.. Les parallèles des parcours dans une nouvelle lecture de la relation entre les deux prophéties